Mortality during the first year of HAART in HIV-1-infected patients in 7 countries from Latin America and the Caribbean Suely H. Tuboi, MD, PhD On behalf.

Slides:



Advertisements
Similar presentations
Tuberculosis incidence and risk factors among adult patients receiving HAART in Senegal: a 7-year cohort study Assane DIOUF et al. IRD/UMR 145 CRCF, CHNU.
Advertisements

Risk factors and true outcomes of children lost to follow-up from antiretroviral therapy in Lilongwe, Malawi C. Ardura Gracia, H. Tweya, C Feldacker, S.
Antiretroviral therapy eligibility at enrollment and time to treatment initiation in Ethiopia Chloe A. Teasdale 1, Chunhui Wang 1, Sileshi Lulseged 1,
STD Screening in HIV Clinics: Value and Implications Thomas Farley, MD MPH Tulane University Deborah Cohen, MD MPH RAND Corporation.
1 Using Biostatistics to Evaluate Vaccines and Medical Tests Holly Janes Fred Hutchinson Cancer Research Center.
Decentralization of HIV care and treatment services in Central Province, Kenya: Adult patient characteristics and outcomes Presenting author: William Reidy,
Patients in routine HIV clinical care at-risk for potentially transmitting HIV in the “test and treat” era of HIV prevention Crane, HM, Mimiaga, M, Feldman,
A Collaborative Analysis of Data from Cohorts in Thailand, South Africa, Botswana, and the United Kingdom International Collaborative Study of Pediatric.
Persisting long term benefit of genotypic guided treatment in HIV infected patients failing HAART and Importance of Protease Inhibitor plasma levels. Viradapt.
Presenter : Dr T. G. Nematadzira on behalf of The IMPAACT PROMISE 1077BF/1077FF Team Efficacy and Safety of Two Strategies to Prevent Perinatal HIV Transmission.
Surveillance to measure impact of ART Theresa Diaz, MD MPH CDC Global AIDS Program.
1 Is Managed Care Superior to Traditional Fee-For-Service among HIV-Infected Beneficiaries of Medicaid? David Zingmond, MD, PhD UCLA Division of General.
The Effect of Syphilis Co-infection on Clinical Outcomes in HIV-Infected Persons The Effect of Syphilis Co-infection on Clinical Outcomes in HIV-Infected.
Complete Recovery of Renal Function After Acute Kidney Injury is Associated with Long-Term All-Cause Mortality In a Large Managed Care Organization Jennifer.
Peter F. Rebeiro, PhD, MHS On behalf of: Carina Cesar, Bryan E. Shepherd, Raquel B. De Boni, Claudia Cortés, Fernanda Rodriguez, Pablo Belaunzarán-Zamudio,
Background There is uncertainty regarding the frequency, predictors, and outcomes of IRIS events Prior studies on IRIS have been limited to convenience.
Fatal and Non-fatal Hepatic Failure in HIV-infected versus HIV-uninfected Persons Enrolled in Kaiser Permanente California (KP), a Large Managed Care Organization.
Transition Program of HIV-infected adolescents to Adult HIV care in Buenos Aires, Argentina S. Arazi Caillaud 1, D. Mecikovsky 1, A.Bordato.
Catherine Kober Margaret Johnson Martin Fisher Caroline Sabin On behalf of UK-CHIC BHIVA/BASHH Manchester 2010 Non-uptake of HAART among patients with.
Management and Development for Health (MDH)
Switch to ATV/r-containing regimen  ATAZIP. Mallolas J, JAIDS 2009;51:29-36 ATAZIP ATAZIP Study: Switch LPV/r to ATV/r  Design  Endpoints –Primary:
Influence of Comorbid Depression and Antidepressant Treatment on Mortality for Medicare Beneficiaries with Chronic Obstructive Pulmonary Disease by SSDI-eligibility.
#735 KA Lichtenstein 1, C Armon 2, K Buchacz 3, AC Moorman 3, KC Wood 2, JT Brooks 3, and the HOPS Investigators 1 University of Colorado Health Sciences.
Antiretroviral Treatment Monitoring: A Canadian Case Example Antiretroviral Treatment Monitoring: A Canadian Case Example Robert Hogg, PhD BC Centre for.
Impact of Highly Active Antiretroviral Therapy on the Incidence of HIV- encephalopathy among perinatally- infected children and adolescents. Kunjal Patel,
EARLY CHILDHOOD OUTCOMES AT THE BOTSWANA- BAYLOR CHILDREN’S CLINICAL CENTRE OF EXCELLENCE: A REPORT TO THE WHO TECHNICAL REFERENCE GROUP ON PEDIATRIC CARE.
David Dowdy, Elvin Geng, Katerina Christopoulos, James Kahn, C. Bradley Hare, Daniel Wlodarczyk, Diane Havlir Internal Medicine Residency Program, UCSF.
Arnold School of Public Health Health Services, Policy, and Management 1 Drug Treatment Disparities Among African Americans Living with HIV/AIDS Carleen.
Switch to LPV/r monotherapy  Pilot LPV/r  M  LPV/r Mono  KalMo  OK  OK04  KALESOLO  MOST  HIV-NAT 077.
Lipoatrophy and lipohypertrophy are independently associated with hypertension: the effect of lipoatrophy but not lipohypertrophy on hypertension is independent.
Factors Associated with Survival in HIV-Infected African Patients on Antiretroviral Therapy: The Impact of a Sampling-Based Approach to Address Losses.
Good Three-year Outcomes of Antiretroviral Therapy at Multiple NGO- assisted facilities in Four Provinces in South Africa Geoffrey Fatti, Ashraf Grimwood.
Comparison of NNRTI vs PI/r  EFV vs LPV/r vs EFV + LPV/r –A5142 –Mexican Study  NVP vs ATV/r –ARTEN  EFV vs ATV/r –A5202.
Failure to Initiate ART, Loss to Follow-up and Mortality among HIV-infected Patients during the pre-ART period in Uganda Elvin H. Geng 1, Winnie Muyindike.
Supported by: NIAID/NHLBI R24 AI067039, NIAID R21 AI Viremia copy-years: A measure of cumulative HIV burden among patients initiating antiretroviral.
Declines in adult HIV mortality in Botswana, : evidence for an impact of antiretroviral therapy programs Rand Stoneburner, Dominic Montagu, Cyril.
MISSING DATA IN THE INFECTIOUS DISEASES INSTITUTE CLINIC DATABASE Agnes N Kiragga East Africa IeDEA investigators’ meeting 4-5 th May 2010 East African.
The immune reconstitution inflammatory syndrome (IRIS) in HIV infected patients comprises a group of inflammatory symptoms associated with the appearance.
Survival Analysis approach in evaluating the efficacy of ARV treatment in HIV patients at the Dr GM Hospital in Tshwane, GP of S. Africa Marcus Motshwane.
Outcomes of Antiretroviral Treatment Programs in Rural Lesotho: Health Centers and Hospitals Compared Niklaus Labhardt, Motlalepula Sello, Mamokone A.
Outcomes in ART treatment programmes with and without access to routine viral load monitoring Olivia Keiser on behalf of IeDEA Southern Africa
THE 6 TH NATIONAL SCIENTIFIC CONFERENCE ON HIV/AIDS Yield and impact of repeated screening for tuberculosis and isoniazid preventive therapy among patients.
1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.
Strategies for Management of Antiretroviral Therapy Study Wafaa El-Sadr and James Neaton for the SMART Study Team.
National Cancer Intelligence Network Outcome and the effect of age in 1318 patients with synovial sarcoma: Report from the National Cancer Intelligence.
A Call to Action Children – The missing face of AIDS.
A Survival Comparison between HIV+ U.S.-born Latinos and Foreign-born Latinos in Houston, Texas Raouf Arafat, MD, MPH, Adebowale Awosika- Olumo.
Response to Antiretroviral Treatment In an Ethiopian Hospital Samuel Hailemariam, MD, MPH; J Allen McCutchan, MD, MSc Meaza Demissie, MD, PMH, PHD; Alemayehu.
Acute Renal Failure in HIV- Infected Individuals Greatly Increases Risk for In-Hospital Mortality Slideset on: Wyatt CM, Arons RR, Klotman PE, Klotman.
HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.
CD4 trajectory among HIV positive patients receiving HAART in a large East African HIV care centre Agnes N. Kiragga 1, Beverly Musick 2 Ronald Bosch, Ann.
Date of download: 6/3/2016 From: U.S. Trends in Antiretroviral Therapy Use, HIV RNA Plasma Viral Loads, and CD4 T-Lymphocyte Cell Counts Among HIV-Infected.
Successfully enrolled in HIV Care but not linked to timely Treatment: Poor retention and Monitoring of Pre-ART patients who are not yet eligible for ART.
Improving Patients Retention in Antiretroviral Treatment Programs: The experience of ARV Programs in Côte d’Ivoire Eugène MESSOU, MD, PhD CePReF- Aconda.
First-Line Treatment of HIV Infection With Either NNRTI- or PI-Based Regimens Effective for Long-term Disease Control Slideset on: MacArthur RD, Novak.
#AIDS2016 Superior Outcomes with Same-Day HIV Testing and ART Initiation Serena Koenig, MD, MPH GHESKIO, Haiti Brigham and Women’s Hospital,
Early survival and clinic retention among high risk HIV-infected patients initiating cART in a pilot Express Care system compared to Routine Care in Western.
AIDS-Defining cancers (n=331) Non-AIDS-Defining cancers (n=75)
BACKGROUND Cancer in Latin American and Caribbean HIV+ populations has not been studied comprehensively. CCASAnet includes sites from Argentina, Brazil,
Earlier treatment and lower mortality in infants Initiating ART at
undetectable (undetectable-6.25)
L.F. Jefferys1, J. Hector1, M.A. Hobbins2, J. Ehmer2, N. Anderegg3
Predictors of antiretroviral treatment associated tuberculosis in Ethiopia: a nested case control study Nebiyu Mesfin, MD.
Better Retention Rates Observed in Patients on Lopinavir than Atazanavir in Uganda
Patients w/AIDS-defining illness
Total Hip Arthroplasty in HIV Positive Patients
Juan Gonzalez Perez AIDS Healthcare Foundation
AIDS-Defining cancers (n=331) Non-AIDS-Defining cancers (n=75)
BACKGROUND Cancer in Latin American and Caribbean HIV+ populations has not been studied comprehensively. CCASAnet includes sites from Argentina, Brazil,
T. Tzellos1,2; H. Yang3; F. Mu3; B. Calimlim4; J. Signorovitch3
Presentation transcript:

Mortality during the first year of HAART in HIV-1-infected patients in 7 countries from Latin America and the Caribbean Suely H. Tuboi, MD, PhD On behalf of CCASAnet – Caribbean, Central and South America network

Background Latin America and the Caribbean largely underrepresented in cohorts assessing HAART effectiveness CCASA-net: – Region 2 of IeDEA (International Databases to Evaluate AIDS) – 8 sites from 7 countries: Argentina, Brazil, Chile, Haiti, Honduras, Mexico, and Peru

Background Objectives of the study: – To describe first year mortality of HIV-infected adult individuals initiating HAART – To assess prognostic factors – To discuss country-specific issues associated with risk of death

Methods Primary outcome – All-cause mortality in the first year of HAART Analysis time – From start of HAART to the earliest of death, last follow-up visit, or 365 days after starting HAART Loss to follow-up – Status not known 1 year after HAART initiation and last visit occurred more than 1 year before the closing date of the database

Methods Statistical analysis – Kaplan-Meier estimates to describe time to outcome – Cox proportional hazards models for each site – Missing values Multiple imputations – Losses to follow-up Inverse probability weighted methods – Comparisons between alive, lost to follow-up, and dead Chi Square Rank sum

Results Number of participants by site and country FH – Argentina (N=794) HUCFF –Brazil (N=522) FA – Chile (N=547) GHESKIO – Haiti (N=1672) IHSS/HE – Honduras (N=329) INNSZ – Mexico (N=416) ImTavH – Peru (N=873)

Results Baseline characteristics of the 5152 patients VariableFH Argentina (794) HUCFF Brazil (522) FA Chile (547) GHESKIO Haiti (1672) IHSS/HE Honduras (328) INNSZ Mexico (416) IMTAvH Peru (873) Female (%) Age (years) Clinical AIDS (%) CD4 count (cells/  L) Regimen type (%) NNRTI based PI based Boosted PI Other

Results Loss to follow-up (LFUP) and mortality rates in the first year of HAART

Results Probability of death in the first year of HAART

Results Probability of death in the first year of HAART adjusted for baseline CD4 A B C M Ha P Ho

Results Factors associated with mortality in the first year of HAART VariableHR (95% Confidence Interval) Male1.09 (0.78 – 1.50) Age ( per 10 years)1.13 (1.02 – 1.25) Clinical AIDS2.93 (2.08 – 4.15) CD4 count (cells/  L) 100 vs (0.68 – 0.93) 200 vs (0.40 – 0.86) 350 vs (0.22 – 0.86) Year of HAART initiation 2003 (ref) (0.86 – 1.35) (0.74 – 1.77) 2006NA Regimen type NNRTI based1.08 (0.86 – 1.35) Other1

Conclusions Overall mortality rate in the first year of HAART similar to that of lower income countries with active follow-up (ART-LINC) Substantial differences between countries Higher mortality rates in Haiti and Honduras independent of baseline CD4 cell count

Conclusions Country-specific factors: – Different stages of disease at HAART initiation Late presentation for care Programme ability to detect candidates for treatment – Age of programme – Different guidelines – Different impact of loss to follow-up

Summary In CCASA-net, the overall reported mortality in the first year of HAART is similar to that of other lower income countries Substantial differences between countries – Differences in programme characteristics Need for operational research

Acknowledgements Bryan Shepherd, Catherine McGowan, Stephany Duda (Vanderbilt University) CCASAnet Steering Group: Pedro Cahn (Argentina), Mauro Schechter (Brazil), Marcelo Wolff (Chile), Jean William Pape (Haiti), Denis Padgett (Honduras), Eduardo Gotuzzo (Peru), Juan Sierra Madero (Mexico), Daniel Masys (USA). CCASAnet Sites: – Fundacion Huesped and Hospital Fernandez (Argentina), – Universidade Federal do Rio de Janeiro (Brazil) – Universidad de Chile (Chile) – GHESKIO (Haiti) – Instituto Hondureño de Seguridad Social and Universidad Autonoma de Honduras (Honduras) – Universidad Peruana Cayetano Heredia (Peru) – Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (Mexico) – Vanderbilt University School of Medicine (USA) National Institutes of Health Program Officer: Melanie Bacon.

Thank you!

Methods Baseline CD4 – Closest to HAART initiation (− 6mo/+7d) Baseline HIV-1 plasma viral load (PVL) – Pre-HAART measurement closest to (− 6mo) Baseline weight – Closest to HAART initiation (+/ − 30d) HAART regimen – PI-based (one PI + two NRTI) – PI-boosted regimens – NNRTI-based (one NNRTI plus two NRTIs) – Nonstandard (any other regimen w/ a minimum of 3 ARVs) Clinical stage of disease – AIDS (WHO stage 4, CDC stage C, or 1986 CDC stage 4) – Non-AIDS – Unknown

Results Adjusted Hazard Ratios and 95%CI for mortality in the first year of HAART

ART-LINC/ART-CC definition of loss to follow-up Initiation Jan/01/2006 Database A close Nov/01/2007 Last visit Oct/01/2006 Jan/01/2007 Lost Not Lost Status 1 year after HAART initiation not known and last visit occurred more than 1 year before the closing date of the database. Database B close Nov/01/2006